Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and sells genetic tests across cancer care, prenatal health, and mental health. Revenue is transactional, generated when clinicians order tests and the company bills insurers, government payers, or patients for laboratory services. Myriad's test portfolio spans hereditary cancer risk (MyRisk, BRACAnalysis CDx), tumor profiling (MyChoice CDx, Precise Tumor, Precise MRD), prenatal screening (Prequel, Foresight, SneakPeek, FirstGene), and pharmacogenomics (GeneSight). The company holds the only FDA-approved germline BRCA companion diagnostic test for breast cancer, with additional FDA approvals in ovarian, pancreatic, and advanced prostate cancers, as of the FY2025 10-K filed February 24, 2026. Reimbursement coverage from private insurers and government payers is a primary driver of volume. Operations are supported by next-generation laboratory facilities, the transition to which was completed in FY2025. Myriad is headquartered in the United States and is incorporated in Delaware.

Revenue model

Transactional laboratory services revenue: Myriad bills payers (private insurers, government programs) or patients per test ordered. Reimbursement coverage levels and coding decisions by payers directly affect realized revenue per test.

Products and services

Hereditary cancer: BRACAnalysis CDx (FDA-approved germline BRCA companion diagnostic for breast, ovarian, pancreatic, advanced prostate cancers), MyRisk Hereditary Cancer panel. Tumor/oncology: MyChoice CDx (HRD status, FDA-approved, validated in more than 20,000 patients), Precise Tumor (pan-cancer NGS comprehensive genomic profiling), Precise MRD (circulating tumor DNA monitoring), Precise Liquid, Precise Oncology Solutions. Prenatal: Prequel (NIPS), Prequel with Amplify, Foresight carrier screen, Foresight Universal Plus, FirstGene (multiple prenatal screen, early access), SneakPeek Early Gender DNA Test. Mental health/pharmacogenomics: GeneSight. Prostate: Prolaris, Urosuite.

Customers and end markets

Ordering clinicians in community medicine and clinical settings across Cancer Care Continuum (hereditary risk, companion diagnostics, comprehensive genomic profiling, MRD monitoring), Prenatal Health, and Mental Health. Payers (private insurers, government programs) are the primary reimbursement source. No specific customer concentration disclosures found in the excerpts.

Value-chain role

Diagnostic laboratory and test developer. Myriad sits between clinicians and payers: it develops assays, runs laboratory testing, reports results to providers, and bills third-party payers. It also holds FDA companion diagnostic approvals that connect its tests to therapeutic eligibility decisions (PARP inhibitor selection).

Geographic exposure

United States primary market. Filing references regulatory requirements in foreign countries, indicating some international presence, but no geographic revenue split is provided in the excerpts.

Source: SEC 10-K, filed 2026-02-24

Industry: In Vitro & In Vivo Diagnostic Substances Peers: Agios Pharmaceuticals Inc Allogene Therapeutics Inc BridgeBio Pharma Inc Travere Therapeutics Inc Iovance Biotherapeutics Inc Ironwood Pharmaceuticals Inc Novavax Inc Vaxcyte Inc Xencor Inc